Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and ...
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: GlobeNewswire
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tumor type with potential for ACR-368 accelerated regulatory approval IND clearance and initial sites activated ahead of timelines for ACR-2316 with first-in-human dosing anticipated in Q4 2024 AP3 Interactome generating proprietary, actionable insights, leveraging in-house data and delivering algorithm-based machine learning-enabled pathway and biomarker analysesAcrivon to host a webcast joined by endometrial cancer key opinion leader Dr. Ramez N. Eskander today, Saturday, September 14 at 9
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumGlobeNewswire
- Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ACRV
Earnings
- 11/13/24 - Miss
ACRV
Sec Filings
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- ACRV's page on the SEC website